Verdiva Bio Presents Preclinical Data on VRB-103, a Selective Oral Amylin Peptide Analog, at 62nd EASD Annual Meeting

Contributed by: Business Wire

Tags

Health

Other Health

Managed Care

General Health

Clinical Trials

Pharmaceutical

Vitamins/Supplements

More Like This

Verdiva Bio Initiates Phase 1 Study of VRB-103, a Selective Oral Amylin Peptide Analog With Weekly Dosing Potential

Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical Officer

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions

PR Newswire associated0

Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association's 84th Scientific Sessions

Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635

Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions

Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting